Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek (beremagene geperpavec-svdt), an investigational non-invasive, topical, redosable gene therapy for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.

Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal Biotech announced in a press release.

Individuals with recessive dystrophic epidermolysis bullosa who have larger wound sizes are more likely to have worsening skin disease severity and quality of life, according to a study.

Researchers will analyze the safety and efficacy of gene-corrected fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, according to a presentation at the South Beach Symposium Medical Dermatology Summit.

The first patient has been dosed in a phase 3 clinical trial of debcoemagene autoficel for the treatment of recessive dystrophic epidermolysis bullosa, Castle Creek Biosciences announced in a press release.